Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Schuler

Showing results (171-180 of 297) with videos related to

Pageof 30
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancerMarcus Schmidt, Dirk Hasenclever, Mitra Schaeffer, et al.
The Lancet. Oncology|June 9, 2015
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6James C-H Yang, Lecia V Sequist, Sarayut Lucien Geater, et al.
Clinical Colorectal Cancer|March 13, 2018
Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal CancerMarcel Wiesweg, Henning Reis, Tobias Köster, et al.
Radiation Oncology (London, England)|September 16, 2021
Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and <sup>18</sup>F-FDG PET/CT for radiotherapy target volume definitionMaja Guberina, Kaid Darwiche, Hubertus Hautzel, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2025
Early years, advanced disease: The unmet need in young adults with non-small cell lung cancerMaximilian Webendoerfer, Marcel Wiesweg, Jane Winantea, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2021
PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPYMaja Guberina, Christoph Poettgen, Martin Metzenmacher, et al.
Cancers|March 28, 2024
Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment-Comparison with Stage III DiseaseMaja Guberina, Christoph Pöttgen, Nika Guberina, et al.
Cancer Science|November 29, 2019
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohortsYung-Jue Bang, Wu-Chou Su, Martin Schuler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 9, 2024
<sup>68</sup>Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical TherapyHelena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, et al.
Respiration; International Review of Thoracic Diseases|April 10, 2026
Independent Validation of the LIONS PREY in Patients Undergoing Navigational BronchoscopyErik Büscher, Faustina Funke, Kaid Darwiche, et al.
Pageof 30

Showing results (171-180 of 297) with videos related to

Sort By:
Pageof 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancerMarcus Schmidt, Dirk Hasenclever, Mitra Schaeffer, et al.
The Lancet. Oncology|June 9, 2015
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6James C-H Yang, Lecia V Sequist, Sarayut Lucien Geater, et al.
Clinical Colorectal Cancer|March 13, 2018
Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal CancerMarcel Wiesweg, Henning Reis, Tobias Köster, et al.
Radiation Oncology (London, England)|September 16, 2021
Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and <sup>18</sup>F-FDG PET/CT for radiotherapy target volume definitionMaja Guberina, Kaid Darwiche, Hubertus Hautzel, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2025
Early years, advanced disease: The unmet need in young adults with non-small cell lung cancerMaximilian Webendoerfer, Marcel Wiesweg, Jane Winantea, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2021
PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPYMaja Guberina, Christoph Poettgen, Martin Metzenmacher, et al.
Cancers|March 28, 2024
Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment-Comparison with Stage III DiseaseMaja Guberina, Christoph Pöttgen, Nika Guberina, et al.
Cancer Science|November 29, 2019
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohortsYung-Jue Bang, Wu-Chou Su, Martin Schuler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 9, 2024
<sup>68</sup>Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical TherapyHelena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, et al.
Respiration; International Review of Thoracic Diseases|April 10, 2026
Independent Validation of the LIONS PREY in Patients Undergoing Navigational BronchoscopyErik Büscher, Faustina Funke, Kaid Darwiche, et al.
Pageof 30